Research
Latest published research we're tracking.
The newest skincare and haircare papers from PubMed, linked to the ingredients we decode. Summaries are the authors' own abstracts — we excerpt, attribute, and link out to the source.
32 papers under Hair loss
Compound Platycladus orientalis tincture promotes hair regrowth and is associated with hair-cycle progression and Wnt/β-catenin-related signaling.
Journal of ethnopharmacology · 2026
ETHNOPHARMACOLOGICAL RELEVANCE: Alopecia is traditionally managed in Chinese medicine using topical botanical preparations aimed at restoring hair-cycle dynamics and improving the follicular microenvironment. Compound Platycladus orientalis tincture (CPT), an ethanol-based polyherbal formulation consisting of Platycladi Cacumen, Szechwan Chinaberry Fruit, and Herba Speranskiae Tuberculatae, has… Read on PubMed →
Assessment and treatment of adolescent hair loss.
Current opinion in pediatrics · 2026
PURPOSE OF REVIEW: Hair loss in adolescents carries significant psychosocial impact, and it is often underrecognized and managed without adolescent-specific approaches. This review describes recent advances in diagnostics, pathophysiology, and therapies to improve diagnosis and management of adolescent alopecia. RECENT FINDINGS: Trichoscopy and ultraviolet-enhanced follicular dermoscopy improve… Read on PubMed →
Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.
Current opinion in pediatrics · 2026
PURPOSE OF REVIEW: To review the current literature for updates on pediatric nonsteroidal topical therapies (NSTT) for the treatment of atopic dermatitis (AD), psoriasis, alopecia areata (AA), vitiligo, and seborrheic dermatitis (SD). RECENT FINDINGS: The FDA approved difamilast and expanded the approved age ranges for roflumilast, tapinarof, and ruxolitinib to treat AD. Recent studies also show… Read on PubMed →
Injectable Therapy for Androgenetic Alopecia: A Systematic Review.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
BACKGROUND: Androgenetic alopecia (AGA) is the leading cause of patterned hair loss. Current therapies are limited, and injectable therapy has emerged for intradermal delivery of bioactive agents. Despite increasing use, protocols and outcomes remain heterogeneous. OBJECTIVE: To systematically evaluate the agents, techniques, efficacy, and adverse effects of injectable therapy for AGA. MATERIALS… Read on PubMed →
Exosome-driven treatments for hair regrowth in androgenetic alopecia: a systematic review of preclinical studies, clinical experiments, safety, and future prospects.
Molecular biology reports · 2026
BACKGROUND: Androgenetic alopecia (AGA) imposes a significant psychosocial burden, yet current treatments such as minoxidil and finasteride often yield suboptimal responses or adverse effects. Exosomes, nanoscale extracellular vesicles derived from mesenchymal stem cells and dermal papilla cells (DPCs), offer a promising regenerative alternative by modulating key hair-growth pathways. This… Read on PubMed →
Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia.
Journal of medicinal chemistry · 2026
Androgenetic alopecia (AGA) is primarily driven by overexpression of androgen receptor (AR) in hair follicles, leading to androgen hypersensitivity and progressive follicular miniaturization. Although PROTAC degraders offer the potential for sustained AR downregulation, their application in AGA has been limited by poor solubility and skin permeability. In this study, we incorporated pyridazinyl… Read on PubMed →
Development and validation of a comprehensive in vitro organ model for androgenetic alopecia.
BMC biotechnology · 2026
BACKGROUND: Male androgenetic alopecia (AGA) is the most common hair loss disorder. However, research on AGA remains limited, primarily due to the lack of clinical samples and imperfect AGA models incapable of replicating the androgen sensitivity of AGA. METHODS: An AGA organ model was established by optimizing the concentration of dihydrotestosterone (DHT) and simulating AGA pathology through… Read on PubMed →
INDIVIDUAL ARTICLE: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss.
Journal of drugs in dermatology : JDD · 2026
Hair loss is a widespread condition with a potentially severe psychological burden, especially among women. The chance of suffering from female alopecia increases with menopause, and topical treatments beyond minoxidil are scarce. Over the past several years, new combinations of natural ingredients and patented mixtures have shown promising results to improve hair shedding, thus helping recover… Read on PubMed →
Living Probiotic Microneedles Coordinate Antiandrogen and Nitric Oxide Therapy for Androgenetic Alopecia.
ACS applied materials & interfaces · 2026
Androgenetic alopecia (AGA) is characterized by follicular miniaturization mediated by androgens along with chronic inflammatory and vascular disturbances. These alterations suggest broader dysregulation involving endocrine pathways, immune activity, and vascular function. Current therapies such as finasteride and minoxidil provide limited and often transient improvement because they target only… Read on PubMed →
Comparative Efficacy of Topical Chitosan and Minoxidil in Hair Loss: A Controlled Study With Microneedling.
The Journal of craniofacial surgery · 2026
BACKGROUND: Chitosan, a natural polysaccharide with immunomodulatory and regenerative properties, has shown promise in enhancing tissue repair. While 5% minoxidil remains the standard treatment for androgenetic alopecia, interest in non-hormonal or adjunctive therapies such as chitosan is growing. OBJECTIVE: To evaluate the clinical efficacy and safety of topical 2% chitosan applied after… Read on PubMed →
Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapy.
The Journal of clinical investigation · 2026
Chemotherapy-induced alopecia (CIA) remains one of the most distressing adverse effects of cancer therapy. Yet, no therapy is available to selectively protect healthy hair follicles (HFs) and their epithelial stem cells (eHFSCs) from chemotherapy-induced damage without awarding potential survival benefits to cancer cells. Here, we report how human HFs can be protected against 2 lead CIA-inducing… Read on PubMed →
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Stem cell research & therapy · 2026
AIMS AND OBJECTIVES: Androgenetic alopecia (AGA) is a common progressive hair loss disorder caused by follicular miniaturization and shortened anagen phases. Conventional treatments mainly target androgen pathways but often yield unsatisfactory results. Regenerative medicine has emerged as a novel therapeutic approach aiming to restore follicular function through biologically active cell-based or… Read on PubMed →
A novel cell-penetrating peptide supports hair follicle growth through anti-inflammatory and growth factor-associated mechanisms in preclinical models.
BMC biotechnology · 2026
BACKGROUND: Hair loss remains a prevalent condition for both men and women worldwide. Current therapies for this condition, including minoxidil and finasteride, are limited by inconsistent efficacy, side effects, and dependence on continuous use. Cell-penetrating peptides (CPPs) have emerged as promising bioactive agents in dermatology due to their ability to traverse cell membranes and modulate… Read on PubMed →
Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study.
Chinese medical journal · 2026
BACKGROUND: Topical finasteride is a novel treatment for men with androgenetic alopecia (AGA). This study aimed to evaluate the efficacy and safety of topical finasteride spray solution in Chinese men with AGA. METHODS: This randomized, double-blind, placebo-controlled, phase III trial enrolled 270 individuals with AGA from 16 sites across China between December 2021 and March 2023. The… Read on PubMed →
Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports.
Expert opinion on drug safety · 2026
BACKGROUND: Topical minoxidil, approved by the FDA in the 1980s, has been widely used to manage androgenetic alopecia. While effective, several adverse events (AEs) related to its use, especially those not well-documented on product labels, remain a concern. OBJECTIVE: This study aimed to evaluate the safety of topical minoxidil by analyzing AEs reported in the FDA Adverse Event Reporting System… Read on PubMed →
Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia.
The Journal of investigative dermatology · 2026
BACKGROUND: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia with generally poor prognosis if untreated and no approved treatment options. OBJECTIVE: The aim of this study was to evaluate changes in the molecular signature of FFA lesions after application of delgocitinib cream. Safety, tolerability, and efficacy were also investigated. METHODS: This was a phase 2a, randomized… Read on PubMed →
Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients.
Actas dermo-sifiliograficas · 2026
BACKGROUND AND OBJECTIVE: Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDOM) has emerged as a… Read on PubMed →
Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study.
Journal of the American Academy of Dermatology · 2026
BACKGROUND: Spironolactone and oral minoxidil are effective female alopecia monotherapies. Combination therapy is commonly used, though safety and tolerability data are limited. OBJECTIVE: To assess safety and tolerability by adverse effect incidence. METHODS: Retrospective cohort study conducted in females aged ≥18 taking combination therapy for hair loss. RESULTS: A total of 432 patients were… Read on PubMed →
Prescribing Habits for Androgenetic Alopecia Among Dermatologists in Spain in 2024: A Cross-Sectional Study.
Actas dermo-sifiliograficas · 2026
The management of androgenetic alopecia (AGA) is evolving. This study updates current prescribing practices compared with 2019-2020. A digital survey was conducted among dermatologists in Spain between March and June 2024, focusing on AGA treatment trends, nutricosmetic product selection, and the adoption of hair skinification. A total of 202 dermatologists participated, including 164 attending… Read on PubMed →
Adjunctive approaches for androgenetic alopecia: A clinical review of nutritional, light-based, topical, and lifestyle interventions.
Journal of the American Academy of Dermatology · 2026
Androgenetic alopecia (AGA) is a chronic, progressive condition with limited Food and Drug Administration-approved treatments. Therefore, there is increasing interest in adjunctive options among patients and physicians. This clinical review synthesizes and critically appraises current evidence on nutritional supplements and nutraceuticals, light-based therapies, topical agents, and lifestyle… Read on PubMed →